|
Sponsored by 
|
|
|
|
|
|
Calif. law that bans drug coupons failed to increase generic use
When officials in California banned coupons for brand-name drug prescriptions, the idea was to boost greater use of cheaper generics.
That, according to a new analysis, hasn't happened, at least not to as great an extent as possible.
After the ban took effect, there was a small, insignificant increase of 0.4% in generic use in California relative to surrounding states, “with no significant change in the trend over time,” researchers wrote in JAMA.
The outcome suggests the law was ineffectual and such an approach is unlikely to sufficiently control spending on prescription drugs.
Read more.
|
A biotech and a medical journal go to battle
Two months ago, Pacira Biosciences took the highly unusual step of filing a libel lawsuit against a medical journal, its editor, and the authors of several published papers, arguing the articles were based on “faulty scientific research” and as a result, its only medicine was portrayed as ineffective.
Now, the American Society of Anesthesiologists, which publishes the medical journal, has fired back. In a court filing to dismiss the lawsuit, the ASA uses scorching language to chastise Pacira and its motives.
Read more.
|
The importance of having an FDA inspection readiness plan for an investigator site
It’s imperative to have a site-specific process and identify who should do what before, during, and after the regulatory inspection. Staff should meet to delegate responsibilities and review all activities for the study under investigation. Learn how your team can prepare prior to the inspection including interview, document, staff, and office preparation. Read more.
|
EU loses bid for faster deliveries of AstraZeneca Covid-19 vaccine
The European Union has failed in its attempt to force AstraZeneca to speed deliveries of its Covid-19 vaccine or face huge fines, the latest round in a high-profile battle between the 27-member bloc and the drug maker.
In its 67-page ruling, a court in Brussels refused to require AstraZeneca to supply 120 million doses by the end of June, which the EU had demanded.
However, the court set a schedule for 80 million doses to be delivered by Sept. 27 and will require AstraZeneca to pay $11.80 for every dose not delivered by that deadline. The court also criticized the drug maker for a “serious breach” of its contract with the EU after repeatedly failing to meet delivery terms.
Read more.
|
More reads
- High hopes for Johnson & Johnson’s Covid vaccine have fizzled in the U.S. (New York Times)
- Models predict U.S. coronavirus infections could surge this fall if vaccination rates lag, former FDA chief says (Washington Post)
|
Thanks for reading! Until tomorrow,
 |
|
